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ABSTRACT
ObjectiveTocomparethecosteffectivenessofnursesand
doctors in performing upper gastrointestinal endoscopy
and flexible sigmoidoscopy.
Design As part of a pragmatic randomised trial, the
economic analysis calculated incremental cost
effectiveness ratios, and generated cost effectiveness
acceptability curves to address uncertainty.
Setting 23 hospitals in the United Kingdom.
Participants 67 doctors and 30 nurses, with a total of
1888 patients, from July 2002 to June 2003.
InterventionDiagnosticuppergastrointestinalendoscopy
and flexible sigmoidoscopy carried out by doctors or
nurses.
Main outcome measure Estimated health gains in QALYs
measured with EQ-5D. Probability of cost effectiveness
over a range of decision makers’ willingness to pay for an
additional quality adjusted life year (QALY).
Results Although differences did not reach traditional
levels of significance, patients in the doctor group gained
0.015 QALYs more than those in the nurse group, at an
increased cost of about £56 (€59, $78) per patient. This
yields an incremental cost effectiveness ratio of £3660
(€3876, $5097) per QALY. Though there is uncertainty
around these results, doctors are probably more cost
effective than nurses for plausible values of a QALY.
Conclusions Though upper gastrointestinal endoscopies
and flexible sigmoidoscopies carried out by doctors cost
slightly more than those by nurses and improved health
outcomes only slightly, our analysis favours endoscopies
by doctors. For plausible values of decision makers’
willingnesstopayforanextraQALY,endoscopydelivered
by nurses is unlikely to be cost effective compared with
endoscopy delivered by doctors.
Trial registration International standard RCT 82765705
INTRODUCTION
Gastrointestinal endoscopy is a common clinical
procedure, and its use is increasing over time. To
meet the increasing demand, endoscopy is becoming
widely practised by nurses in the United Kingdom.
1
Therehasbeenlittleevaluationofthecosteffectiveness
of procedures undertaken by nurses rather than by
doctors.
Consideration of the economics of diagnostic
procedures can be complex as the cost effectiveness
of the consequent treatment of any discovered condi-
tion needs to be considered. Economic evaluations of
screening tests often estimate a “cost per condition
detected,”whichisdeterminedpartlybythesensitivity
and specificity of the test. We focused not on the cost
effectiveness of endoscopy itself but on whether or not
thereisadifferenceinendoscopydeliveredbydoctors
or nurses. We took a pragmatic approach to the
evaluation of this complex intervention,
2 in which we
assumed that it is the method of delivery (nurse or
doctor) that is under consideration, not the inter-
ventionitself.Weassessedrelativecosteffectivenessas
part of a pragmatic randomised controlled trial under-
taken in the UK.
3
METHODS
Study design and interventions
In the cost effectiveness analysis we addressed two
issues: the decision about who should undertake the
intervention and the level of uncertainty around this
decision.
45 The incremental cost effectiveness ratio
represents the relation between costs and outcomes
and thus facilitates decision making. We characterised
the uncertainty associated with this decision by
estimating the probability that nurse delivered endo-
scopyiscosteffectiveoverarangeofvaluesofdecision
makers’ willingness to pay for an additional quality
adjusted life year (QALY).
Theclinicalstudy,ofwhichthiseconomicevaluation
was part, was a pragmatic randomised trial in 23
hospitals in England, Scotland, and Wales.
6 A total of
1888 patients were allocated at random to either a
doctor or a nurse for upper gastrointestinal endoscopy
or flexible sigmoidoscopy. We collected health out-
come measures at baseline, one day, one month, and
one year after the intervention. Further details of the
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are described elsewhere.
3 We take a UK National
HealthService(NHS)perspectivewitheffectsassessed
in terms of health gains measured in QALYs. As the
timehorizonofthestudywasoneyear,discountingwas
not appropriate. We did not extrapolate beyond one
yearasthestudywasnotpoweredtodetectdifferences
betweengroupsinfactorsinfluencinglongtermhealth
outcomes. We used Bayesian analysis in which the
parameters have probability distributions. Thus it was
possible, and appropriate, to compute the probability
of an event being effective or cost effective.
Data collection and outcome measures
We extracted information on resources used during
endoscopy of trial patients from resource time sheets.
Informationcollectedincludeddurationofendoscopy,
number of patients undergoing endoscopy, staffing,
and consumables used (except for therapeutic proce-
dures).Thedurationofprocedureswastimedfromthe
extubationofonepatienttothe extubationofthe next.
We obtained data on resource use after the endo-
scopy from examination of patients’ medical records
and patients’ questionnaires administered at baseline
and 12 months (table 1). We estimated the cost of the
intervention from data on the duration of intervention
from the clinical trial multiplied by figures for the cost
perminute(fordoctorornurse)estimatedfromNetten
andCurtis.
7Table 2showsunitcostestimatesin2002-
3 prices.
We used the EQ-5D instrument
8 to measure
patients’ health states and to ascribe values to those
states. This instrument measures health across five
dimensions (mobility, self care, usual activities, pain
and discomfort, and anxiety and depression). Patients
have three possible responses(no problems, moderate
problems, or severe problems) for each of these
dimensionstoreflecttheirperceivedtheirhealthstates.
This puts each into one of 245 mutually exclusive
health states (the 243 states arising from the EQ-5D,
plus unconscious, and dead), each valued on a scale
from 0 (representing death) to 1 (representing perfect
health).
WeconvertedallEQ-5Dscoresto“utilities”through
a tariff derived from a representative UK population
sample.
9WecomparedmeanQALYsgeneratedinthe
two groups over the 12 month period. We plotted
utilityatbaselineandsubsequentpointsandcalculated
theareaunderthecurvetoestimateQALYsgained(or
lost) by each patient. This reflects the fact that the
QALY is the product of time and utility
10 and assumes
that changes in utility over time follow a linear path.
11
We adjusted these estimates for baseline EQ-5D as
recommended by Manca et al
12 and included sex and
age ascovariates. In a subgroup analysiswe separately
consideredthecosteffectivenessofsigmoidoscopyand
oesophagogastroduodenoscopy.
Analysis
Resource use and EQ-5D data were missing in several
patients, with some missing both. For analysis we
assumed that data were missing at random. We used
two methods to impute missing data. For EQ-5D, we
used the last value carried forward, as patients’ last
score is likely to be the best predictor of the missing
value. For resource use we used regression to impute
missing values from age, sex, and EQ-5D scores.
Traditionally, cost effectiveness analyses estimate
incremental cost effectiveness ratios from mean
differences in costs and effects between treatment and
controlgroups,and 95%confidence intervalsfromthe
independent samples t test. As interpretation of
incremental cost effectiveness ratios derived from
more than one quadrant of the cost effectiveness
plane is problematic,
13 we calculated net monetary
benefit
14 for each group from trial and imputed data.
15
To calculate patient specific net monetary benefits we
multiplied each patient’s QALYs by the assumed
maximum value of a QALY and subtracted that
patient’s costs. We used these patient specific net
monetary benefits to derive cost effectiveness accept-
abilitycurvesandestimatedtheaggregatebenefitfrom
the equation:
where λ is the decision maker’s maximum willingness
to pay for a QALY. For example, if treatment A has a
mean cost of £100000 and generates a mean of five
QALYs with a QALY valued at £30000, then the net
Table 1 |Details of resource use data and unit costs
Item of resource use Source of resource use Source of unit cost data
NHS staff and time Resource time sheet recorded during
endoscopy lists
UK NHS salary scales
Inpatient stay Hospitalmedicalrecordsexaminedatoneyear UK NHS reference costs
Outpatient
appointments
Patient questionnaires plus hospital medical
records and primary care records at one year
UK NHS reference costs
GP visits Patient questionnaires plus hospital medical
records and primary care records at one year
Unitcosts ofhealthand social care
4
Medical management,
such as drugs
Patient questionnaires and GP questionnaire British National Formulary
Travel to and from
appointments
Patientquestionnairesatbaseline,onemonth,
and one year
AA
Private medical care Patientquestionnairesatbaseline,onemonth,
and one year
Unitcosts ofhealthand social care
4
AA=Automobile Association.
Maximum willingness to pay per additional QALY (£)
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Fig 1 | Cost effectiveness acceptability curve
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£50000 ((5×£30000)−£100000).
Thus the net monetary benefit depends on the value
of the QALY, and analysis shows how sensitive the
results are to changes in this value. The uncertainty
around the net monetary benefit can estimate the
probability that a strategy is cost effective through the
cost effectiveness acceptability curve. This is a graphi-
cal representation of the probability of an intervention
being cost effective over a monetary range for a
decision maker’s willingness to pay for an additional
unit of health gain. We used the values 0 (which
assumes outcomes are equivalent or not valued),
£1000, £10000, £20000, £30000, and £50000 as
examples of the decision maker’s willingness to pay
for one extra QALY.
RESULTS
Missing data
At baseline utility data were missing for 184 patients
(10%), either because they did not complete the
questionnaire or because one of the items within the
EQ-5D was missing. This figure increased to 489
patients(26%)atonemonthand576(31%)atoneyear.
For data on resource use we examined the medical
records of 1674 patients (89%); 606 patients (32%) did
not report number of attendances in general practice.
There were no significant differences in characteristics
of patients with and without missing data.
Resource use
Table 3 presents mean levels of resource use. These
estimates arise from responders to questionnaires
without imputation. For most variables, the nurse
based programme increased resource use (table 3).
Endoscopy by nurses was followed by slightly more
use of all primary care resources except home visits
from general practitioners. In secondary care there
were increased attendances at day hospital and out-
patient clinics. These differences were small, however,
and did not reach conventional levels of significance.
Health states
Therewaslittleeffectineithergrouponusualactivities
or self care. Both groups showed an increased
proportion of patients in the least severe pain and
discomfort and anxiety and depression groups, and
these differences favoured endoscopy delivered by
doctors(table 4).Mobilitydeterioratedinbothgroups,
withthenursegroupagainperformingslightlylesswell
than the doctor group. These results were consistent
with the clinical effectiveness results as measured by
the condition specific gastrointestinal symptom rating
questionnaire.
3 Three of the four factors measured at
one year favoured the doctor group, though none of
these differences reached significance.
3
QALYs
From these estimates, which included values imputed
for missing values, we estimated changes in EQ-5D
overoneyear(table 5).Inturnweusedtheseestimates
to generate QALYs.
Though differences were small, the gain in QALYs
wasgreaterafterendoscopybydoctorsthanbynurses.
This is partly explained by difference in baseline
characteristics, notably the EQ-5D score at baseline.
AdjustmentforthesereducedthedifferenceinQALYs
to 0.0153 (95% confidence interval −0.008 to 0.039)
(table 5). We used this estimate in the construction of
costeffectivenessacceptabilitycurves,whichreflectthe
findingthatEQ-5Dscoreatbaselinewashigherforthe
doctor group.
WhilethisdifferenceinQALYsseemstobesmallin
absolute terms, it equates to a difference of five to six
days of additional perfect health each year. There are
severalplausibleexplanationsfortheimprovedQALY
scores for doctors. The most likely scenario is that
nurses requested more subsequent tests and investiga-
tions. Such tests and investigations might have a
negative effect on patients’ wellbeing and it is possible
that this manifested itself in lower QALY scores in the
nurse group.
Total cost
Table 5showsestimateddifferencesincostperpatient
betweengroups,includingthecost oftheintervention.
As there was uncertainty around these estimates, the
difference was not significant at conventional levels.
The intervention cost more in the doctor group
because doctors’ time costs more than nurses’ time.
Table 3 |Mean resource use in two groups over 12 month study period
Doctor group
(n=953)
Nurse group
(n=928) Mean difference (95% CI)
General practitioner:
Home visits 0.30 0.17 0.13 (−0.04 to 0.29)
Surgery visits 4.81 5.05 −0.24 (−0.72 to 0.24)
Practice nurse:
Surgery visits 1.43 1.56 −0.13 (−0.47 to 0.22)
Home visits 0.03 0.11 −0.08 (−0.22 to 0.05)
Day hospital attendances 0.27 0.35 −0.08 (−0.14 to 0.01)
Inpatient length of stay 1.10 1.10 0.00 (−0.53 to 0.53)
Outpatient attendances 1.34 1.46 −0.13 (−0.32 to 0.06)
Intervention time (minutes) 23.50 22.41 1.09 (−1.95 to 4.13)
Table 2 |Unit costs of resources used
Unit cost (£) in 2002-3 prices4
General practitioner:
Home visits (cost per visit) 61
Surgery visits 20
Practice nurse
Home visit 18
Surgery visits 10
Day hospital attendances 74
Inpatient cost per day 269-484
Outpatient attendances 75-110
Intervention (cost per min) 0.53 nurse, 1.82 doctor
RESEARCH
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between groups. In addition patients allocated to
doctors had slightly higher costs in both primary and
secondarycare.Thedifferencesincostsassociatedwith
resourceuse in primary and secondarycare was small.
Though in absolute terms there were (slightly) more
contacts in both primary and secondary care in the
nursegroupthaninthedoctorgroup,thedoctorgroup
wasassociatedwithmorecostlyresources,particularly
salary costs. Adjustment for total costs for baseline
differences in age and sex made no meaningful
difference to the results.
Incremental cost effectiveness ratio (ICER)
Thedoctorgroupgenerated0.0153moreQALYsthan
the nurse group, at a net cost of £56 per patient. This
resulted in an incremental cost effectiveness ratio of
£3660perQALY.Therewasmuchuncertaintyaround
these results, and neither the difference in patients’
outcomes nor that in costs approached traditional
levels of significance. Therefore we used the net
monetary benefit approach and generated cost effec-
tiveness acceptability curves.
Net monetary benefits and cost effectiveness
acceptability curves
Figure 1 shows the cost effectiveness acceptability
curveforvaluesofaQALYbetweenzeroand£50000.
Attaching no value to a QALY yields a probability of
about 78% of the nurse group being cost effective,
implying a chance of 78% that nurses reduced costs.
Theprobabilityofnursesbeingcosteffective,however,
decreases as the value of a QALY increases and as
doctors become more cost effective. At a value of
£30000perQALY,oftenstatedtobetheborderlinefor
the NHS, nurses have only a 13% chance of being cost
effective. Indeed, for all plausible values of a QALY,
doctorsaremorelikelytobecosteffectivethannurses.
There is, however, much uncertainty around this
result; the cost effectiveness scatter in figure 2 shows
the plots of incremental costs and incremental effects
for doctors compared with nurses.
Sensitivity analysis
Though this stochastic analysis addresses intrinsic
uncertainty, sensitivity analysis is still appropriate to
check on methodological uncertainty, specifically
uncertainty arising from data imputation and from
different forms of endoscopy.
WehadcompletemedicalrecordsandEQ-5Ddatafor
440 patients, 227 (51.6%) in the nurse group and 213
(48.4%) in the doctor group, reflecting the distribution of
patientsbetweengroupsinthefulltrial.Mostmissingdata
omitted a single cost or a single EQ-5D dimension at
baseline or follow-up. The resulting estimates were
similar to those with imputed data: doctors cost £40
more than nurses (−£148 to £231) but generated 0.021
more QALYs (−0.02to 0.06). This yields an incremental
costeffectivenessratioof£2060,lowerthanwithimputed
data. The smaller sample, however, leads to more
uncertainty:theprobabilityofdoctorsbeingcosteffective
never exceeds 84%, whatever the value of a QALY.
Sigmoidoscopy v oesophagogastroduodenoscopy
Sigmoidoscopy showed an incremental cost effective-
ness ratio of £2600 per QALY for doctors.
Table 4 |Number(percentage)ofpatientsineachEQ-5Ddimension(healthstate 1(best),2,or3(worst))bygroupatbaseline,one month,andoneyearfollow-up
Baseline One month One year
123 123 12 3
Doctor group (n=836):
Mobility 579 (69) 257 (31) 0 580 (69) 254 (30) 2 (0.2) 567 (68) 268 (32) 1 (0.1)
Self care 761 (91) 75 (9) 0 744 (89) 92 (11) 0 739 (88) 93 (11) 4 (1)
Usual activities 476 (60) 328 (39) 33 (4) 471 (56) 327 (39) 39 (5) 472 (57) 326 (39) 37 (4)
Pain/discomfort 176 (21) 570 (68) 89 (11) 250 (30) 517 (62) 69 (8) 263 (32) 498 (60) 74 (9)
Anxiety/depression 423 (51) 369 (44) 44 (5) 468 (56) 323 (39) 45 (5) 452 (54) 344 (41) 39 (5)
Nurse group (n=868):
Mobility 596 (69) 268 (31) 4 (0.5) 588 (68) 278 (32) 3 (0.3) 565 (65) 301 (35) 2 (0.2)
Self care 786 (91) 80 (9) 2 (0.2) 766 (88) 99 (11) 3 (0.3) 768 (89) 97 (11) 3 (0.3)
Usual activities 470 (54) 367 (42) 30 (4) 465 (54) 368 (42) 35 (4) 474 (55) 361 (42) 33 (4)
Pain/discomfort 179 (21) 591 (68) 98 (11) 234 (27) 559 (64) 75 (9) 247 (28) 536 (62) 85 (10)
Anxiety/depression 455 (52) 356 (41) 57 (7) 483 (56) 334 (39) 51 (6) 479 (55) 331 (38) 58 (7)
Cost difference (£)
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for doctors, resulting in a higher ratio of £7850. Both
ratios, however, would be acceptable for most reason-
ablevaluesofadecisionmaker’swillingnesstopayfor
a QALY.
DISCUSSION
Principal findings
Patients undergoing endoscopy carried out by doctors
gained 0.015 QALYs more than those treated by
nurses, at an increased cost of around £56 per patient,
yielding an incremental cost effectiveness ratio of
£3660 per QALY. Doctor delivered endoscopywould
therefore seem to be acceptably cost effective. The
analysis also suggests that, for most reasonable values
of a decision maker’sw i l l i n g n e s st op a yf o ra n
additional QALY, endoscopy delivered by nurses is
unlikely to be cost effective comparedwith endoscopy
delivered by doctors based on the evidence of this
single trial analysis. There is considerable uncertainty
around these estimates, which indicates that further
research might be needed.
Strengths and weaknesses
We used a randomised trial to compare the cost
effectiveness of doctors and nurses performing endo-
scopy. There were missing data both on resource use
and patients’ utility. While imputing these data is not
ideal, the results of that imputation are robust, as
analysislimitedtocompletecasesyieldssimilarresults.
The study lasted only one year, though there is
potential for later effects in this population—for
example, missed diagnoses. A longer trial would be
ideal, but the similarity of immediate and delayed
complications between nurses and doctors suggests
thereislittledifferenceintheirlongtermperformance.
It is possible that the use of the EQ-5D and the
resultingestimates of QALYsare not sensitive enough
in these patients to identify differences in their health
related quality of life. The results of our economic
analysis, however, are similar to those of the clinical
analysis in that there was a non-significant effect in
favour of doctors.
Hence the QALY gain was greater one year after
endoscopy by doctors than by nurses. This is despite
patients being more satisfied with endoscopies
performed by nurses. This does not imply inconsis-
tency, as short term gains in satisfaction probably
reflectdifferencesinprocess,whilemediumtermgains
in quality of life reflect patients’ perception of out-
comes, perhaps in the form of the accuracy of the
procedure and their confidence in the results.
Nurse endoscopists might not have reached “steady
state” in experience and confidence. As their experi-
ence grows, they might become more confident and
therefore order fewer follow-up tests. The higher
frequency of tests and interventions in the nurse
group, however, might reflect intrinsic differences
between the professions in terms of attitudes to risk.
Meaning of the study
Though there is debate over the appropriate NHS
thresholdcost per QALY,Rawlins and Culyer
16 argue
that the National Institute for Health and Clinical
Excellence would be unlikely to reject a technology
withacostofbetween£5000and£15000perQALYon
grounds of cost effectiveness. On the evidence of this
trial,therefore,doctordeliveredendoscopyseemscost
effective.
This result might surprise some as upper gastro-
intestinal endoscopies and sigmoidoscopies by nurses
cost slightly less than doctors and the difference in
healthoutcomesissmallanddoesnotreachtraditional
levelsofsignificance.Oureconomicanalysisestimates
the probability of cost effectiveness from the uncer-
tainty around the estimates of costs and effects, rather
than discarding differences that do not reach “sig-
nificance.” Hence this methodological paradigm leads
to a different interpretation of our results from that
adopted in the clinical effectiveness paper.
6
Interpretationdepends on the paradigm chosenand
the factors under consideration by decision makers.
Classic statistical inference fails to reject the null
hypotheses that there is no difference in effectiveness
or cost effectiveness between endoscopy delivered by
doctors and nurses. Policy makers might therefore
view nurse endoscopists as an acceptably safe and
effective way of changing skill mix in health care,
releasing medical resources and increasing the role of
nurse specialists. In contrast with the classic statistical
approach, economic inference in this context makes
decisions by comparing the estimated cost per QALY
Table 5 |Mean EQ-5D scores, QALYs, and costs (£) per patient over 12 months by group
Doctor group (n=931) Nurse group (n=957) Difference (95% CI)
Mean EQ-5D scores:
Baseline 0.700 0.689 0.011 (−0.014 to 0.040)
One month 0.713 0.697 0.016 (−0.009 to 0.041)
One year 0.710 0.693 0.017 (−0.008 to 0.043)
QALYs 0.712 0.695 0.0153* (−0.008 to 0.039)
Primary care costs 135 128 7 (−3 to 15)
Secondary care costs 565 538 27 (−127 to 181)
Intervention costs 39 16 23 (20 to 26)
Total cost 739 683 56 (−100 to 213)
*Difference in QALYs allows for baseline differences in EQ-5D, sex, and age.
WHAT IS ALREADY KNOWN ON THIS TOPIC
To meetincreasingdemandfor gastrointestinalendoscopy,
nurses are increasingly undertaking both upper and lower
endoscopy in the UK
Clinicalstudies,mainlyobservationalandnon-randomised,
have established the safety and acceptability of this, but
there has been little evaluation of the cost effectiveness
WHAT THIS PAPER ADDS
Though there is uncertainty around the results, doctors are
likely to be more cost effective than nurses for plausible
values of a QALY
RESEARCH
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would pay for a QALY. In this trial this leads to the
conclusion that upper gastrointestinal endoscopy and
sigmoidoscopy delivered by doctors would be cost
effective at a typical threshold. Bayesian analysis goes
further by estimating the probability that the inter-
vention is cost effective in the sense that the estimated
cost per QALY exceeds a given threshold. In this trial
this form of analysis leads to the conclusion that the
averagedoctorendoscopisthasaprobabilityof80-90%
of being more cost effective than the average nurse
endoscopistatcommonlyusedvaluesofwillingnessto
pay for a QALY. Policy makers or hospital decision
makers pursuing efficiency alone would therefore
choose endoscopy delivered by doctors.
Unanswered questions
The choice of skill mix in endoscopy might be
influenced by factors other than cost effectiveness,
such as affordability, staff shortages, and access to
health care, all of which enter into policy decisions. At
the start of this trial there was concern about shortages
of medical staff but, after the expansion of medical
schools, concerns shifted to surpluses and potential
unemployment of junior doctors.
17 Endoscopy deliv-
eredbynurses,inthecurrentstateoftheirtrainingand
experience, is unlikely to be cost effective compared
with endoscopy delivered by doctors. As nurses grow
inexperienceovertimeitwillbeimportanttocontinue
to monitor both effectiveness and cost effectiveness.
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